COR	LOE	RECOMMENDATIONS
1	A	1. For patients with AF and an estimated annual thromboembolic risk of ≥2% per year (eg, CHA2DS2-VASc score of ≥2 in men and ≥3 in women), anticoagulation is recommended to prevent stroke and systemic thromboembolism.1-7
1	A	2. In patients with AF who do not have a history of moderate to severe rheumatic mitral stenosis or a mechanical heart valve, and who are candidates for anticoagulation, DOACs are recommended over warfarin to reduce the risk of mortality, stroke, systemic embolism, and ICH.1-7
2a	A	3. For patients with AF and an estimated annual thromboembolic risk of ≥1% but <2% per year (equivalent to CHA2DS2-VASc score of 1 in men and 2 in women), anticoagulation is reasonable to prevent stroke and systemic thromboembolism.1,3
3: Harm	B-R	4. In patients with AF who are candidates for anticoagulation and without an indication for antiplatelet therapy, aspirin either alone or in combination with clopidogrel as an alternative to anticoagulation is not recommended to reduce stroke risk.8,9
3: No Benefit	B-NR	5. In patients with AF without risk factors for stroke, aspirin monotherapy for prevention of thromboembolic events is of no benefit.10,11